



**Fresenius Kabi USA, LLC**

Three Corporate Drive  
Lake Zurich, Illinois 60047  
T 847-550-2300  
T 888-391-6300  
[www.fresenius-kabi.com/us](http://www.fresenius-kabi.com/us)

November 2024

Dear Fresenius Kabi trading partner,

This letter is regarding FDA notice of DSCSA Exemptions from Section 582(g)(1) and Other Requirements of the FD&C Act for Certain Trading Partners, issued in October this year. Fresenius Kabi USA, LLC, is eligible for the exemption and will utilize the exemption until May 27, 2025.

As a manufacturer, Fresenius Kabi USA, LLC, intends to continue to provide lot-level traceability data via the ASN (Advance Shipping Notice), including the T3 (Transaction Information, Transaction Statement, and Transaction History). At the same time, Fresenius Kabi USA, LLC, intends to further refine our systems and processes to provide accurate and consistent item-level T2 data (Transaction Information and Transaction Statement) electronically and will continue working toward that end.

Finally, when the T2 information is fully required for all sectors of the US supply chain, Fresenius Kabi USA, LLC, will continue to provide the ASN for the convenience of our trading partners but it will no longer serve to meet the DSCSA compliance requirement.

Sincerely,  
Fresenius Kabi USA, LLC DSCSA Team

[Waivers and Exemptions Beyond the Stabilization Period | FDA](#)